23/06/2026
| The future of Indian Pharma will not be shaped by innovation alone, it will be shaped by the ecosystems that make innovation possible.
This vision set the tone for IIM Indore’s Industry Conclave on “Next Era of Innovation in the Indian Pharma Sector,” where experts came together to explore the evolving landscape of pharmaceutical innovation.
In his inaugural address, Prof. Manish Popli, Dean (Planning & Development), IIM Indore, highlighted India’s transition from manufacturing excellence to knowledge-driven ecosystems, emphasizing the need to transform innovative ideas into impactful ex*****on.
Building on this theme, Mr. Anil Matai, Director General, OPPI, spoke about the importance of moving from a volume-driven to a value-driven pharmaceutical industry and strengthening India’s capabilities in innovation and R&D to compete with global leaders.
Adding an industry perspective, Mr. Ashutosh Inamdar, CEO & VP, Lupin Life Sciences Ltd., underscored the importance of quality standards, affordable healthcare access, and the growing potential of trade generics in expanding healthcare reach, particularly across rural India.
The panel was moderated by Prof. Punyashlok Dwibedy, Chair, Industry Interface Office.
The discussions further explored how partnerships, policy support, regulatory frameworks, entrepreneurship, and leadership will play a defining role in positioning India as a global pharmaceutical innovation powerhouse.
The conclave reinforced a shared belief: while scientific breakthroughs remain critical, the next era of Indian Pharma will be defined by collaboration, sustainable impact, and strong innovation ecosystems that connect academia, industry, startups, investors, and policymakers.
